These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19124439)

  • 1. Cardiovascular disease in chronic kidney disease.
    Saran AM; DuBose TD
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):425-34. PubMed ID: 19124439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease and cardiovascular disease: a case presentation.
    McCarley PB; Salai PB
    Nephrol Nurs J; 2007; 34(2):187-98; quiz 199-200. PubMed ID: 17486949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses.
    Lucas SM; Nuss G; Stern J; Lotan Y; Sagalowsky AI; Cadeddu JA; Raj GV
    Cancer; 2008 Nov; 113(10):2681-6. PubMed ID: 18853420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survey of risk factors and renal disease in first-degree relatives of dialysis patients].
    Inserra F; de la Llave G; Alpino M; Castagna R; de la Fuente I; Dorado E; Norbis M; Pinelli L; Puddu M; Santos JC; Vivas N; Marelli C
    Medicina (B Aires); 2007; 67(1):8-18. PubMed ID: 17408015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods.
    Imai E; Matsuo S; Makino H; Watanabe T; Akizawa T; Nitta K; Iimuro S; Ohashi Y; Hishida A;
    Hypertens Res; 2008 Jun; 31(6):1101-7. PubMed ID: 18716357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension in moderate-to-severe nondiabetic CKD patients.
    Segura J; Ruilope LM
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):23-7. PubMed ID: 21224027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L; Kaskel FJ; Bamgbola O
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients.
    Fernandez-Fresnedo G; Rodrigo E; de Francisco AL; de Castro SS; Castañeda O; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S246-9. PubMed ID: 17130269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
    Ripley E
    Am Heart J; 2009 Jun; 157(6 Suppl):S7-S16. PubMed ID: 19450722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic renal insufficiency and cardiovascular disease].
    Charriere S; Rognant N; Chiche F; Cremer A; Deray G; Priou M
    Ann Cardiol Angeiol (Paris); 2009 Feb; 58(1):40-52. PubMed ID: 18937921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia in chronic kidney disease: managing a high-risk combination.
    Chauhan V; Vaid M
    Postgrad Med; 2009 Nov; 121(6):54-61. PubMed ID: 19940417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic kidney disease as a situation of high added risk in hypertensive patients.
    Segura J; García-Donaire JA; Praga M; Ruilope LM
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S136-40. PubMed ID: 16565238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
    Ratto E; Leoncini G; Viazzi F; Pontremoli R
    G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease and cardiovascular disease--using the ANNA Standards and Practice Guidelines to improve care. Part 1: the epidemiology of chronic kidney disease: the risk factors and complications that contribute to cardiovascular disease.
    McCarley PB; Burrows-Hudson S
    Nephrol Nurs J; 2006; 33(6):666-74; quiz 675-6. PubMed ID: 17219728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.